Back to top

cancer: Archive

Shaun Pruitt

Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?

Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.

AZNPositive Net Change PFEPositive Net Change MRNAPositive Net Change

Kevin Cook

Bull of the Day: Lantheus (LNTH)

Medical diagnostics leader in prostate cancer is driving 34% sales and 32% EPS growth

LNTHNegative Net Change

Neena Mishra

Biotech ETFs Pop on M&A Resurgence

2023 could be a year of heightened biotech dealmaking activity

GSKPositive Net Change NVSPositive Net Change PFEPositive Net Change MRKPositive Net Change AMGNPositive Net Change GILDPositive Net Change VRTXPositive Net Change IBBPositive Net Change SGENPositive Net Change RXDXPositive Net Change XBIPositive Net Change SBIONegative Net Change BTECPositive Net Change IBBQPositive Net Change

Shaun Pruitt

Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition

Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.

PFEPositive Net Change SGENPositive Net Change

Kevin Cook

Bull of the Day: Lantheus (LNTH)

Stunning "beat-and-raise" quarter has analysts scrambling to raise estimates and price targets above $110

LNTHNegative Net Change

Sundeep Ganoria

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

ADAPNegative Net Change KMDAPositive Net Change ZYMENegative Net Change

Shaun Pruitt

Buy this Medical Sector Pioneer Stock

Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.

GILDPositive Net Change AMGNPositive Net Change MRNAPositive Net Change

Bryan Hayes

How Markets Have Fared Under a Divided Congress

Markets typically applaud the 'certainty' that comes with a split Congress.

LLYNegative Net Change

Shaun Pruitt

Pfizer Earnings Preview: Growth & Diversification is Key

Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely on the growth of other business units during the quarter.

PFEPositive Net Change JNJPositive Net Change ABBVPositive Net Change

Shaun Pruitt

Should Investors Buy Bristol Myers Squibb Stock?

BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.

BMYPositive Net Change PFEPositive Net Change

Bryan Hayes

Bull of the Day: Unum Group (UNM)

Unum Group has consistently enhanced shareholders' value through dividend hikes and share buybacks.

UNMPositive Net Change

Kevin Cook

Bull of the Day: Illumina (ILMN)

Leader in genomic sequencing still growing sales over 15% as lifescience labs crunch more genetic data

ILMNPositive Net Change NTRANegative Net Change

Bryan Hayes

Healthcare Outperformance May Signal Short-Term Market Bottom

This sector outperformance may be a sign the market is nearing a point of selling exhaustion.

JNJPositive Net Change XLVPositive Net Change

Bryan Hayes

BioPharma Giants Print Fresh All-Time Highs

The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.

REGNPositive Net Change BMYPositive Net Change

Bryan Hayes

Bull of the Day: Pfizer Inc. (PFE)

With a dividend yield of 3% and a top Zacks VGM score of 'A', it's not hard to see why PFE is a top stock pick.

PFEPositive Net Change

Bryan Hayes

The Death Rate Soared Last Year - But Not Why You Might Think

3 Funeral Services Stocks Hitting All-Time Highs

CSVPositive Net Change SCIPositive Net Change HIPositive Net Change

Kevin Cook

Bull of the Day: Mesa Laboratories (MLAB)

Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy

MLABPositive Net Change DHRPositive Net Change PACBPositive Net Change NVTAPositive Net Change NTRANegative Net Change

Kevin Cook

Bear of the Day: NeoGenomics (NEO)

Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff

NEOPositive Net Change EXASPositive Net Change NVTAPositive Net Change NTRANegative Net Change GHNegative Net Change

Kevin Cook

Bull of the Day: Exact Sciences (EXAS)

EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year

EXASPositive Net Change ADPTNegative Net Change NVTAPositive Net Change NTRANegative Net Change GHNegative Net Change

Kevin Cook

Bear of the Day: Guardant Health (GH)

Cancer detection innovator with liquid biopsy saw analysts slash estimates as R&D investment costs rise

GHNegative Net Change EXASPositive Net Change

Kevin Cook

Bear of the Day: CRISPR Therapeutics (CRSP)

Gene editors got a big boost recently from sickle cell potential and Cathie Wood's thematic investing

CRSPNegative Net Change EDITPositive Net Change ARKKNegative Net Change NTLAPositive Net Change ARKGNegative Net Change

Kevin Cook

Bull of the Day: Hologic (HOLX)

This leader in women's health diagnostics is ramping high double-digit growth on COVID testing

QDELPositive Net Change HOLXPositive Net Change